

Special Issue

Clostridioides difficile Infection, 2nd Edition

Message from the Guest Editor

The first volume of the Special Issue “*Clostridioides difficile* Infection” was published in 2021. It was a successful issue, with 9 published papers. These papers shed light on several aspects of this complex disease, including the *Clostridioides difficile* infection (CDI) clinical course and the mortality rate in different settings and patients’ case mix, the novel risk factors for CDI recurrence and novel therapeutic approaches. This result encouraged us to open a second volume on the same topic. As a continuation of the Special Issue published in 2021, this second volume will also deliver an invaluable compendium of the latest studies on any aspects concerning CDI.

Guest Editor

Dr. Guido Granata

Clinical and Research Department, National Institute for Infectious Diseases “L. Spallanzani” IRCCS, Rome, Italy

Deadline for manuscript submissions

closed (31 March 2024)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/92408

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)